Medigen Vaccine Biologics (6547) — Cash Flow Reinvestment Rate
Medigen Vaccine Biologics (6547) has a Cash Flow Reinvestment Rate of 3.00x as of December 2025, reinvesting NT$303.54 Million (capex NT$3.54 Million plus investments NT$300.00 Million) from operating cash flow of NT$101.08 Million. See Medigen Vaccine Biologics free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Medigen Vaccine Biologics Cash Flow Reinvestment Rate (2015–2024)
Historical reinvestment intensity for Medigen Vaccine Biologics across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Medigen Vaccine Biologics.
Annual Cash Flow Reinvestment Rate for Medigen Vaccine Biologics (2015–2024)
Year-by-year capital reinvestment analysis for Medigen Vaccine Biologics. See Medigen Vaccine Biologics (6547) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.64x | NT$1.09 Billion | NT$40.75 Million | NT$34.98 Million | ▲ +1419.1% |
| 2021 | 1.75x | NT$1.02 Billion | NT$579.89 Million | NT$134.97 Million | ▼ -17.1% |
| 2015 | 2.11x | NT$457.15 Million | NT$216.26 Million | NT$457.15 Million | — |